Global Dengue Testing Market Size Grows at a Staggering CAGR of 4.95%

Introduction

Straits Research released its highly anticipated report, “Global Dengue Testing Market Size & Outlook, 2026-2034.” According to the study, the global market size is valued at USD 639.12 million in 2025 and is projected to expand to USD 983.70 million by 2034, registering a compound annual growth rate (CAGR) of 4.95%.

Market Dynamics

The market growth is primarily attributed to the rising prevalence of dengue infections worldwide, increasing demand for early and accurate diagnostic solutions, and strong government initiatives to strengthen surveillance in endemic regions. In addition, increasing awareness among healthcare providers and the public about early detection of dengue is driving demand for diagnostic tests. For example, in September 2025, as per the Ministry of Health and Family Welfare, India’s Ministry of Health conducted nationwide awareness campaigns emphasizing early diagnosis, vector control, and timely testing to reduce dengue outbreaks. This rising awareness drives demand for rapid and reliable dengue diagnostic solutions, which further enhances the market growth. Moreover, increasing international travel and rapid urbanization in tropical regions contribute to dengue spread, thereby boosting the need for dengue testing. For example, in June 2025, as per the Centers for Disease Control and Prevention, the U.S. reported rising imported dengue cases due to international travel from endemic countries. Such a factor presents a significant market opportunity for laboratories, hospitals, and POC testing providers to expand services for early detection and outbreak control.

Market Highlights

• Product: The ELISA-Based Tests segment dominated the market in 2025 with a revenue share of 45.64%, fuelled by its high sensitivity and specificity, ability to process large sample volumes, and widespread use in confirmatory diagnostics.
• Type: The POC Servicesegment is expected to witness the highest CAGR (5.89%) during the forecast period. 
• End User: The Clinical Labs segment dominated the market in 2025 with a revenue share of 44.16% during the forecast period.
• Regional Insights: North America dominates the market with a 72% share, fuelled by the high prevalence of dengue cases due to stronger travel-related dengue screening programs and expanded border health checks. 

Competitive Players

1. Hoffmann-La Roche Ltd
2. Abnova Corporation
3. Abbott
4. Thermo Fisher Scientific Inc.
5. InBios International, Inc.
6. Globetech Media
7. PerkinElmer, Inc.
8. CERTEST BIOTEC
9. DiaSorin S.p.A
10. Quest Diagnostics
11. Grifols Diagnostic Solutions Inc,
12. Accuquik Test Kits.
13. ACCESS BIO
14. AdvaCare Pharma
15. Jiangsu BioPerfectus Technologies Co., 
16. Intec.
17. Prometheus Bio Inc.
18. iCare Medical
19. Hangzhou Lysun Biotechnology Co., Ltd.
20. Neo-Nostics
21. Others

Recent Developments

Segmentation

1. By Product (2026-2034)
   1. ELISA-based tests
   2. Dengue IgG/IgM Detection Kits
   3. RT PCR tests
   4. Rapid Diagnostic Tests (RDTs)
   5. NS1 Antigen Detection Kits
   6. Lateral Flow Immunoassay
2. By Type (2026-2034)
   1. Centralized Service
   2. POC Service
3. By End User (2026-2034)
   1. Hospitals
   2. Diagnostic Centers
   3. Clinical Labs
   4. Others